INTENSITY AND DISTRIBUTION OF IMMUNOHISTOCHEMICAL EXPRESSION OF GALECTIN-3 IN THYROID NEOPLASMS

Dubravka Mateša-Anić1, Sandra Moslavac2, Neven Mateša1, Hrvoje Čupić4 and Zvonko Kusić3

1University Department of ENT and Head and Neck Surgery, Rijeka University Hospital Center, Rijeka; 2Department of Clinical Cytology, Sunce Polyclinic; 3University Department of Oncology and Nuclear Medicine, 4Ljudevit Jurak University Department of Pathology, Sestre milosrdnice University Hospital Center, Zagreb, Croatia

SUMMARY – The aim of the study was to assess the intensity and distribution of galectin-3 expression in benign and malignant thyroid neoplasms by immunohistochemical method. Immunohistochemical expression of galectin-3 was analyzed in surgical thyroid specimens from 82 patients with histopathologic diagnosis of follicular adenoma (n=32), Hürthle cell adenoma (n=10) and papillary carcinoma (n=40). Results of intracytoplasmatic and intranuclear expression of galectin-3 were scored using a semi-quantitative scale for intensity. Intracytoplasmatic expression of galectin-3 was positive in 18 (43%) benign neoplasms and in all 40 malignant neoplasms. The accuracy, sensitivity and specificity of intracytoplasmatic expression of galectin-3 as a malignant marker in thyroid neoplasms were 78.1%, 100% and 57.1%, respectively. Intracytoplasmatic expression of galectin-3 was positive in 10 (31%) cases of follicular adenoma and 8 (80%) cases of Hürthle cell adenoma. The accuracy, sensitivity and specificity of intranuclear expression of galectin-3 as a malignant marker in thyroid neoplasms were 84.1%, 100% and 69%, respectively. There was no strong intensity of either intracytoplasmatic or intranuclear expression of galectin-3 in benign thyroid neoplasms, and no weak intensity of either intracytoplasmatic or intranuclear expression of galectin-3 in malignant neoplasms. There was no statistically significant difference between intracytoplasmatic and intranuclear expression of galectin-3 in benign thyroid neoplasms. The results of our study indicate that the immunohistochemical expression of galectin-3 is a highly sensitive marker of malignancy, with low specificity in differentiating malignant from benign thyroid neoplasms. The analysis of intensity and distribution of galectin-3 expression could improve the specificity of the method.

Key words: Galectin-3; Immunohistochemistry; Thyroid tumors

INTRODUCTION

With the advent of the era of molecular pathology, some researchers believe that traditional evaluation of H&E-stained slides may be at the brink of extinction, while others believe that traditional H&E-staining still is and will remain the ‘gold standard’ of diagnostic pathology. Molecules that may be expressed during the crucial steps in the development of malignancy are expected to have strong effects on clinical management.

Although postsurgical analysis of tumor architecture usually provides the current criteria for definitive evidence of malignancy in thyroid neoplasms, distinction of hyperplastic nodules from papillary carcinoma or follicular carcinoma can be difficult. In encapsulated neoplasms composed exclusively of follicles and...
lacking capsular and vascular invasion, distinction between follicular adenoma and follicular variant of papillary carcinoma rests on the pathologist’s perception of nuclear characteristics of follicular cells. Furthermore, differentiation between follicular adenoma and follicular carcinoma may be difficult in cases of minimally invasive follicular carcinoma.

Several molecular markers have been reported to be helpful in distinguishing between benign and malignant follicular-patterned lesions of the thyroid. Among them, the most promising is a beta-galactoside-binding protein galectin-31-13. Despite its high sensitivity, some authors have reported its expression in benign thyroid lesions, contributing to its lower specificity14-16.

In the current study, we used the immunohistochemistry method to study the intensity and distribution of galectin-3 expression in surgical material from benign and malignant thyroid neoplasms. Our aim was to evaluate the efficiency of galectin-3 expression as a molecular marker of malignancy.

**Patients and Methods**

The patients included in this study were assigned from University Department of ENT and Head and Neck Surgery, Sestre milosrdnice University Hospital Center, Zagreb, Croatia. We analyzed the immunohistochemical expression of galectin-3 in surgical thyroid specimens from 82 patients with histopathologic diagnosis of follicular adenoma (n=32), Hürthle cell adenoma (n=10) and papillary carcinoma (n=40).

For immunohistochemistry, mouse monoclonal antibody to galectin-3 (Novocastra, UK; 1:100) was prepared according to the manufacturer’s instructions. Immunohistochemistry was performed using the indirect avidin-biotin complex immunoperoxidase method.

Results of intracytoplasmatic and intranuclear expression of galectin-3 were scored using a semi-quantitative scale for intensity: negative (-), weak (+), moderate (++), or strong (+++).

Sensitivity, specificity, predictive value, and diagnostic accuracy were assessed to evaluate the efficiency of galectin-3 as a malignant marker in thyroid neoplasms.

Data analysis was performed using statistical χ²-test or Fisher exact test.

**Results**

*Intracytoplasmatic expression of galectin-3*

Intracytoplasmatic expression of galectin-3 was positive in 18 (43%) benign neoplasms and in all 40 malignant neoplasms (100%) (Fig. 1). There was a statistically significant difference in the intracytoplasmatic expression of galectin-3 between benign and malignant thyroid neoplasms (p<0.01) (Table 1).

**Table 1. Intracytoplasmatic expression of galectin-3 in benign and malignant thyroid neoplasms**

<table>
<thead>
<tr>
<th></th>
<th>Galectin-3 positive</th>
<th>Galectin-3 negative</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Benign neoplasms</td>
<td>18</td>
<td>24</td>
<td>42</td>
</tr>
<tr>
<td>Malignant neoplasms</td>
<td>40</td>
<td>0</td>
<td>40</td>
</tr>
</tbody>
</table>

Fisher exact test: p<0.01
There was a statistically significant difference in intracytoplasmatic expression of galectin-3 in papillary carcinoma vs. follicular adenoma (Fisher exact test: p<0.01), and in papillary carcinoma vs. Hürthle cell adenoma (Fisher exact test: p<0.05).

**Intranuclear expression of galectin-3**

Intranuclear expression of galectin-3 was positive in 13 (31%) benign neoplasms and in all 40 malignant neoplasms (100%). There was a statistically significant difference in intranuclear expression of galectin-3 between benign and malignant thyroid neoplasms (p<0.01) (Table 3). The accuracy, sensitivity and specificity of intranuclear expression of galectin-3 as a malignant marker in thyroid neoplasms were 84.1%, 100% and 69%, respectively. Positive and negative predictive values were 75.5% and 100%, respectively.

Intranuclear expression of galectin-3 was positive in 7 (22%) cases of follicular adenoma and 6 (60%) cases of Hürthle cell adenoma. There was a statistically significant difference in intranuclear expression of galectin-3 between follicular adenoma and Hürthle cell adenoma (p<0.05) (Table 4).

**Intensity of intracytoplasmatic and intranuclear expression of galectin-3**

In 82 patients, the intensity of intracytoplasmatic and intranuclear expression of galectin-3 was analyzed separately. There was no strong intensity of either intracytoplasmatic or intranuclear expression of galectin-3 in benign thyroid neoplasms, and no weak intensity of either intracytoplasmatic or intranuclear expression of galectin-3 in malignant neoplasms. There was a statistically significant difference in the intensity of expression of galectin-3 between benign and malignant thyroid neoplasms (p<0.01) (Tables 5 and 6).

**Intracytoplasmatic vs. intranuclear expression of galectin-3**

Intracytoplasmatic and intranuclear expression of galectin-3 was present in all malignant thyroid neoplasms. Intracytoplasmatic expression of galectin-3 was positive in 18 benign thyroid neoplasms, and intranuclear expression of galectin-3 was positive in 13 (72%) of these cases too. There were no cases of only intranuclear expression of galectin-3. We found
no statistically significant difference in intracytoplasmatic vs. intranuclear expression of galectin-3 in benign thyroid neoplasms (Fisher exact test: p=0.8180), follicular adenomas (Fisher exact test: p=0.3204) and Hürthle cell adenomas (Fisher exact test: p=0.2380).

Discussion

In this study, all malignant thyroid neoplasms were found to express galectin-3; however, a substantial number (43%) of benign thyroid neoplasms also expressed galectin-3. A few studies have reported negative galectin-3 expression in all benign thyroid lesions and high galectin-3 expression in common malignant thyroid neoplasms. Later studies produced conflicting results. The conflicting results reported by various authors may be because they chose to accept different thresholds of galectin-3 immunostaining as true positive staining, or used different galectin-3 antibodies. Besides, the interpretation of immunohistochemical staining is very subjective and can be technically difficult. Coli et al. and Martins et al. found immunohistochemical expression of galectin-3 in 63% and in 45% of follicular adenomas, respectively. Maruta et al. found positive immunostaining of galectin-3 in 25% of follicular adenoma FNA samples. In our study, we found intracytoplasmatic and intranuclear immunohistochemical expression of galectin-3 in 31% and 22% of follicular adenomas, respectively.

Niedziela et al. found Hürthle cells present in 6 of 10 galectin-3 positive aspirates, of which 5 lesions were benign. Mateša et al. found a statistically significant relationship between the presence of Hürthle cells and positive expression of galectin-3 in Hashimoto thyroiditis aspirates and a tendency of such a relationship in nodular goiter aspirates analyzed by RT-PCR method. In this study, intracytoplasmatic and intranuclear immunohistochemical expression of galectin-3 was found in 80% and 60% of Hürthle cell adenomas, respectively. We found a statistically significant difference in the expression of galectin-3 between follicular adenomas and Hürthle cell adenomas.

Martins et al. found strong galectin-3 immunostaining in half of papillary carcinomas, and no weak or negative staining in this group. They also found strong galectin-3 immunostaining in only 2 (6%) of 31 follicular adenomas. Hermann et al. found strong galectin-3 immunostaining in the majority of malignant lesions, and only focal reactivity in a few benign adenomatous lesions. In our study, there was no strong intensity of either intracytoplasmatic or intranuclear expression of galectin-3 in benign thyroid neoplasms, and no weak or negative expression, intracytoplasmatic or intranuclear, of galectin-3 in malignant neoplasms.

Immunohistochemical analysis revealed galectin-3 to be distributed predominantly in the cytoplasm with occasional nuclear localization. Mills et al. found positive, both intracytoplasmatic and intranuclear, galectin-3 immunostaining in the cytoblocks of papillary carcinoma. In our study, we found both intracytoplasmatic and intranuclear expression of galectin-3 in all malignant thyroid neoplasms. Intracytoplasmatic expression of galectin-3 was more often present in benign thyroid neoplasms than intranuclear expression of galectin-3, but the difference was not statistically significant. There were no cases of only intranuclear expression of galectin-3.

In conclusion, the results of our study indicate that the immunohistochemical expression of galectin-3 is a highly sensitive marker of malignancy, with low specificity in differentiating malignant from benign thyroid neoplasms. The analysis of intensity and distribution of galectin-3 expression could improve the specificity of the method.

References

1. ROSAI J. The continuing role of morphology in the molecular age. Mod Pathol 2001;14:258-60.
4. ASA SL. How familial cancer genes and environmentally induced oncogenes have changed the endocrine landscape. Mod Pathol 2001;14:246-53.
Sažetak

INTENZITET I RASPODJELA IMUNOHISTOKEMIJSKE EKSPRESIJE GALEKTINA-3 KOD NOVOTVORINA ŠTITNJAČE

D. Mateša-Anić, S. Moslavac, N. Mateša, H. Ćupić i Z. Kusić

Cilj istraživanja bio je imunohistokemijskom metodom utvrditi intenzitet i raspodjelu ekspresije galektina-3 u malignim i benignim tumorima štitnjače. Analizirana je imunohistokemijska ekspresija galektina-3 u kirurškim materijalima 82 bolesnika od kojih je 32 imalo histopatološku dijagnozu folikularnog adenoma, 10 adenoma hürthleovih stanica i 40 papilarnog karcinoma. Intenzitet intracitoplazmatske i intranuklearne ekspresije galektina-3 određivan je semikvantitativno. Intracitoplazmatska ekspresija galektina-3 bila je pozitivna u 18 (43%) benignih tumora i kod svih 40 malignih tumora. Pouzdanost, osjetljivost i specifičnost intracitoplazmatske ekspresije galektina-3 kao biljega malignosti bile su 78,1%, 100% i 57,1%. Intracitoplazmatska ekspresija galektina-3 bila je pozitivna u 10 (31%) folikularnih adenoma i u 8 (80%) adenoma Hürthleovih stanica. Pouzdanost, osjetljivost i specifičnost intranuklearne ekspresije galektina-3 kao biljega malignosti bile su 84,1%, 100% i 69%. Nije bilo jakog intenziteta ekspresije, bilo intracitoplazmatske ili intranuklearne, galektina-3 kod benignih tumora štitnjače, niti je bilo slabog intenziteta ekspresije, bilo intracitoplazmatske ili intranuklearne, galektina-3 kod malignih tumora. Nije nađena statistički značajna razlika između intracitoplazmatske i intranuklearne ekspresije galektina-3 kod benignih tumora štitnjače. Istraživanje je pokazalo da je imunohistokemijska ekspresija galektina-3 visoko osjetljiva kao biljega malignosti, ali s niskom specifičnošću u odnosu na benign tumore štitnjače. Analiza intenziteta i raspodjele ekspresije galektina-3 može poboljšati specifičnost ove metode.